tetano
Editor, Senior Moderator
J Crohns Colitis
. 2023 Nov 6:jjad182.
doi: 10.1093/ecco-jcc/jjad182. Online ahead of print. Antibody responses to Influenza vaccination are diminished in patients with inflammatory bowel disease on infliximab or tofacitinib
Zhigang Liu[SUP] 1 [/SUP], James L Alexander[SUP] 1 2 [/SUP], Kai Yee Eng[SUP] 1 [/SUP], Hajir Ibraheim[SUP] 1 2 [/SUP], Sulak Anandabaskaran[SUP] 1 3 [/SUP], Aamir Saifuddin[SUP] 1 3 [/SUP], Laura Constable[SUP] 1 [/SUP], Rocio Castro Seoane[SUP] 1 [/SUP], Claire Bewshea[SUP] 4 [/SUP], Rachel Nice[SUP] 4 5 [/SUP], Andrea D'Mello[SUP] 6 [/SUP], Gareth R Jones[SUP] 7 8 [/SUP], Sharmili Balarajah[SUP] 1 2 [/SUP], Francesca Fiorentino[SUP] 9 10 [/SUP], Shaji Sebastian[SUP] 11 12 [/SUP], Peter M Irving[SUP] 13 14 [/SUP], Lucy C Hicks[SUP] 1 2 [/SUP], Horace R T Williams[SUP] 1 2 [/SUP], Alexandra J Kent[SUP] 15 [/SUP], Rachel Linger[SUP] 16 [/SUP], Miles Parkes[SUP] 16 17 [/SUP], Klaartje Kok[SUP] 18 [/SUP], Kamal V Patel[SUP] 19 [/SUP], Julian P Teare[SUP] 1 2 [/SUP], Daniel M Altmann[SUP] 20 [/SUP], Rosemary J Boyton[SUP] 21 22 [/SUP], Ailsa L Hart[SUP] 3 [/SUP], Charlie W Lees[SUP] 7 8 [/SUP], James R Goodhand[SUP] 4 23 [/SUP], Nicholas A Kennedy[SUP] 4 23 [/SUP], Katrina M Pollock[SUP] 21 24 [/SUP], Tariq Ahmad[SUP] 4 23 [/SUP], Nick Powell[SUP] 1 2 [/SUP]; VIP study investigators
Affiliations
Background and aims: We sought to determine whether six commonly used immunosuppressive regimens were associated with lower antibody responses after seasonal influenza vaccination in patients with IBD.
Methods: We conducted a prospective study including 213 IBD patients and 53 healthy controls; 165 who had received seasonal influenza vaccine and 101 who had not. IBD medications included infliximab, thiopurines, infliximab and thiopurine combination therapy, ustekinumab, vedolizumab or tofacitinib. The primary outcome was antibody responses against influenza/A H3N2 and A/H1N1, compared to controls, adjusting for age, prior vaccination and interval between vaccination and sampling.
Results: Lower antibody responses against influenza A/H3N2 were observed in patients on infliximab (Geometric Mean Ratio 0.35 [95% CI 0.20-0.60], p=0.0002), combination of infliximab and thiopurine therapy (0.46 [0.27-0.79], p=0.0050) and tofacitinib (0.28 [0.14-0.57], p=0.0005) compared to controls. Lower antibody responses against A/H1N1 were observed in patients on infliximab (0.29 [0.15-0.56], p=0.0003), combination of infliximab and thiopurine therapy (0.34 [0.17-0.66], p=0.0016), thiopurine monotherapy (0.46 [0.24-0.87], p=0.017) and tofacitinib (0.23 [0.10-0.56], p=0.0013). Ustekinumab and vedolizumab were not associated with reduced antibody responses against A/H3N2 or A/H1N1. Vaccination in the previous year was associated with higher antibody responses to A/H3N2. Vaccine-induced anti-SARS-CoV-2 antibody concentration weakly correlated with antibodies against H3N2 (r=0.27; p=0.0004) and H1N1 (r=0.33; p<0.0001).
Conclusions: Vaccination in both the 2020-2021 and 2021-2022 seasons was associated with significantly higher antibody responses to influenza/A than no vaccination or vaccination in 2021-2022 alone. Infliximab and tofacitinib are associated with lower binding antibody responses to Influenza/A, similar to COVID-19 vaccine-induced antibody responses.
Keywords: JAK-inhibitor; anti-TNF; humoral immunity; immunisation.
. 2023 Nov 6:jjad182.
doi: 10.1093/ecco-jcc/jjad182. Online ahead of print. Antibody responses to Influenza vaccination are diminished in patients with inflammatory bowel disease on infliximab or tofacitinib
Zhigang Liu[SUP] 1 [/SUP], James L Alexander[SUP] 1 2 [/SUP], Kai Yee Eng[SUP] 1 [/SUP], Hajir Ibraheim[SUP] 1 2 [/SUP], Sulak Anandabaskaran[SUP] 1 3 [/SUP], Aamir Saifuddin[SUP] 1 3 [/SUP], Laura Constable[SUP] 1 [/SUP], Rocio Castro Seoane[SUP] 1 [/SUP], Claire Bewshea[SUP] 4 [/SUP], Rachel Nice[SUP] 4 5 [/SUP], Andrea D'Mello[SUP] 6 [/SUP], Gareth R Jones[SUP] 7 8 [/SUP], Sharmili Balarajah[SUP] 1 2 [/SUP], Francesca Fiorentino[SUP] 9 10 [/SUP], Shaji Sebastian[SUP] 11 12 [/SUP], Peter M Irving[SUP] 13 14 [/SUP], Lucy C Hicks[SUP] 1 2 [/SUP], Horace R T Williams[SUP] 1 2 [/SUP], Alexandra J Kent[SUP] 15 [/SUP], Rachel Linger[SUP] 16 [/SUP], Miles Parkes[SUP] 16 17 [/SUP], Klaartje Kok[SUP] 18 [/SUP], Kamal V Patel[SUP] 19 [/SUP], Julian P Teare[SUP] 1 2 [/SUP], Daniel M Altmann[SUP] 20 [/SUP], Rosemary J Boyton[SUP] 21 22 [/SUP], Ailsa L Hart[SUP] 3 [/SUP], Charlie W Lees[SUP] 7 8 [/SUP], James R Goodhand[SUP] 4 23 [/SUP], Nicholas A Kennedy[SUP] 4 23 [/SUP], Katrina M Pollock[SUP] 21 24 [/SUP], Tariq Ahmad[SUP] 4 23 [/SUP], Nick Powell[SUP] 1 2 [/SUP]; VIP study investigators
Affiliations
- PMID: 37941436
- DOI: 10.1093/ecco-jcc/jjad182
Background and aims: We sought to determine whether six commonly used immunosuppressive regimens were associated with lower antibody responses after seasonal influenza vaccination in patients with IBD.
Methods: We conducted a prospective study including 213 IBD patients and 53 healthy controls; 165 who had received seasonal influenza vaccine and 101 who had not. IBD medications included infliximab, thiopurines, infliximab and thiopurine combination therapy, ustekinumab, vedolizumab or tofacitinib. The primary outcome was antibody responses against influenza/A H3N2 and A/H1N1, compared to controls, adjusting for age, prior vaccination and interval between vaccination and sampling.
Results: Lower antibody responses against influenza A/H3N2 were observed in patients on infliximab (Geometric Mean Ratio 0.35 [95% CI 0.20-0.60], p=0.0002), combination of infliximab and thiopurine therapy (0.46 [0.27-0.79], p=0.0050) and tofacitinib (0.28 [0.14-0.57], p=0.0005) compared to controls. Lower antibody responses against A/H1N1 were observed in patients on infliximab (0.29 [0.15-0.56], p=0.0003), combination of infliximab and thiopurine therapy (0.34 [0.17-0.66], p=0.0016), thiopurine monotherapy (0.46 [0.24-0.87], p=0.017) and tofacitinib (0.23 [0.10-0.56], p=0.0013). Ustekinumab and vedolizumab were not associated with reduced antibody responses against A/H3N2 or A/H1N1. Vaccination in the previous year was associated with higher antibody responses to A/H3N2. Vaccine-induced anti-SARS-CoV-2 antibody concentration weakly correlated with antibodies against H3N2 (r=0.27; p=0.0004) and H1N1 (r=0.33; p<0.0001).
Conclusions: Vaccination in both the 2020-2021 and 2021-2022 seasons was associated with significantly higher antibody responses to influenza/A than no vaccination or vaccination in 2021-2022 alone. Infliximab and tofacitinib are associated with lower binding antibody responses to Influenza/A, similar to COVID-19 vaccine-induced antibody responses.
Keywords: JAK-inhibitor; anti-TNF; humoral immunity; immunisation.